A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Pemetrexed; Drug: Pembrolizumab; Drug: Carboplatin; Drug: Cisplatin Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study